Poltreg S.A. (WSE: PTG)
Health Care · Biotechnology · PL
zł19.55
+0.26% today · -28.4% 1Y
Poltreg S.A. (WSE: PTG) operates in the Biotechnology industry within the Health Care sector. The company is valued at $29.79M and employs 34 people.
Over the last twelve months the share price has lost 28.4%, trading between 16.00 and 29.50.
Tweenvest scores Poltreg S.A. across four factors: quality 40/100, value 20/100. Its strongest factor is quality.
PTG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $29.79M
- Revenue (TTM)
- $63.78K
- P/E
- —
- EPS
- -4.97
- Dividend yield
- —
- Beta (5Y)
- 0.83
- 52-week high
- zł29.50
- 52-week low
- zł16.00
- Avg volume (3M)
- —
- Shares outstanding
- 5.92M
- Employees
- 34
- Next earnings
- —
About Poltreg S.A.
Poltreg S.A. is a biotechnology enterprise based in Gdansk, Poland, specializing in the creation of therapeutic solutions for autoimmune conditions. The company's research and development efforts are centered on harnessing T-regulatory cells to develop treatments, specifically targeting type 1 diabetes in children and multiple sclerosis.
- ISIN
- PLPLTRG00038
- Founded
- 2015
- Listed since
- Nov 23, 2021
- Exchange
- Warsaw Stock Exchange
- Currency
- PLN
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Genenta Science S.p.A.NasdaqCM: GNTA | $30.38M | $0.63 | -0.01% |
| Aligos Therapeutics, Inc.NasdaqCM: ALGS | $30.35M | $4.86 | -8.99% |
| Immunotech Biopharm LtdSEHK: 6978 | $30.29M | HK$0.39 | -4.94% |
| BriaCell Therapeutics Corp.TSX: BCT | $30.01M | CA$4.88 | -13.01% |
| Nicox S.A.ENXTPA: ALCOX | $29.74M | €0.30 | -2.91% |
| Cleo Diagnostics LtdASX: COV | $29.57M | AU$0.31 | -1.59% |
| Parataxis Korea, Inc.KOSDAQ: A288330 | $29.36M | ₩— | — |
| Medicenna Therapeutics Corp.TSX: MDNA | $29.36M | CA$0.45 | +3.45% |
Figures last refreshed Oct 18, 2026.